United Therapeutics director files initial insider report

United Therapeutics Corp director Victor J. Dzau has filed an initial Form 3, establishing him as a reporting person for UTHR equity.

Accepted by SEC EDGAR 07/23/2026 - 04:47 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

United Therapeutics Corp director Victor J. Dzau has filed an initial Form 3, establishing him as a reporting person for UTHR equity. Disclosed information shows he is a director, not an officer or ten percent owner, and that no insider transactions or derivative positions are reported.

Key Figures

Buy transactions: 0 Sell transactions: 0 Derivative transactions: 0 +1 more

4 metrics

Buy transactions 0 Buy transactions reported for Victor J. Dzau in the Form 3

Sell transactions 0 Sell transactions reported for Victor J. Dzau in the Form 3

Derivative transactions 0 Derivative security transactions reported in the transaction summary

Ten percent owner indicator 0 Indicator that Victor J. Dzau is not a ten percent owner of UTHR

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Victor J. Dzau’s Form 3 for UTHR indicate?

The Form 3 shows that Victor J. Dzau is a director of United Therapeutics Corp and not a ten percent owner. It reports no insider transactions or derivative positions associated with him at the time of this initial ownership statement.

Is Victor J. Dzau a ten percent owner of UNITED THERAPEUTICS (UTHR)?

No. The Form 3 identifies Victor J. Dzau as not a ten percent owner of UNITED THERAPEUTICS Corp. He is reported solely in his capacity as a director, with no additional ownership status indicated.

Are any stock purchases or sales reported for Victor J. Dzau in UTHR?

No transactions are reported. The Form 3 data show zero buy transactions and zero sell transactions for Victor J. Dzau, meaning no purchases, sales, or other insider trades are disclosed in this initial statement.

Does the UTHR Form 3 for Victor J. Dzau report any derivative securities?

No. The derivative section for Victor J. Dzau shows no derivative positions reported, and the transaction summary lists no derivative transactions, exercises, or restructurings related to options or similar instruments.

What role does Victor J. Dzau hold at UNITED THERAPEUTICS Corp (UTHR)?

He is identified as a director of UNITED THERAPEUTICS Corp. The Form 3 confirms he is not an officer and not classified as a ten percent owner, clarifying the capacity in which he is a reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

DZAU VICTOR J

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MARYLAND 20910

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/22/2026

3. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

No securities are beneficially owned.

	/s/ John S. Hess, Jr. under Power of Attorney	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)